, Volume 10, Issue 6, pp 546–551 | Cite as

A Case for the Adoption of Pharmacoeconomic Guidelines in Japan

  • Shunya Ikeda
  • Naoki Ikegami
  • Adam J. Oliver
  • Mie Ikeda
Leading Article


In recent years, more and more Japanese pharmaceutical companies have been submitting pharmacoeconomic data to the government. following the official request that such data may help in setting pharmaceutical prices. The companies have cooperated because. by doing so. they could influence pricing decisions for new products. However, the quality of these data at present is considered to be poor and heavily biased.

The introduction of pharmacoeconomic guidelines that outline a set of standardised factors to be included in evaluations are necessary, so that an appropriate comparison of the cost effectiveness of the many new drugs that are introduced into the Japanese market each year can be made. In addition to supporting the development of standardised guidelines, the Ministry of Health and Welfare should clarify how pharmacoeconomic data are to be used to aid policy decisions and also mandate the publication of pharmacoeconomic data.


Pharmacoeconomic Analysis Pharmaceutical Firm Health Econ Pharmacoeconomic Data Pharmaceutical Price 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Commonwealth Department of Human Services and Health.Guidelines for the pharmaceutical industry on preparation ofsubmissions to the pharmaceutical benefits advisory committee-including major submissions involving economic analyses.Canberra: Australian Government Publishing Service.Google Scholar
  2. 2.
    Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals:Canada. 1st ed. Ottawa: CCOHTA. Nov 1994Google Scholar
  3. 3.
    Drummond MF. Rutten F. Brenna A. et al. Economic evaluations of pharmaceuticals: a European perspective. Pharmacoeconomics1993; 4: 173–86PubMedCrossRefGoogle Scholar
  4. 4.
    Inoue S. Kitazawa S. Oliver A. et al. Present situation of pharmacoeconomic evaluation by Japanese pharmaceutical companies(abstract P6]. First Annual International Meeting forthe Association for Pharmacoeconomics and Outcomes Research:1996 May 12; PhiladelphiaGoogle Scholar
  5. 5.
    Ikegami N. Pharmaceutical prices. quantities and innovation: comparing Japan with the US. Pharmacoeconomics 1994; 6:424–33PubMedCrossRefGoogle Scholar
  6. 6.
    The Ministry of Health and Welfare. Administrative Announcement; 30 September 1994. Tokyo: Ministry of Health andWelfare. 1994Google Scholar
  7. 7.
    Freemantle N. Maynard A. Something rotten in the state of clinical and economic evaluations. Health Econ 1994; 3: 63–7PubMedCrossRefGoogle Scholar
  8. 8.
    Mason J. Drummond M. Reporting guidelines for economic studies. Health Econ 1995; 4: 85–94PubMedCrossRefGoogle Scholar
  9. 9.
    Briggs A. Sculpher M. Sensitivity analysis in economic evaluation: a review of published studies. Health Econ 1995; 4:355–71PubMedCrossRefGoogle Scholar
  10. 10.
    Ikeda S. Noguchi N. Oliver A. et al. A review of pharmacoeconomic studies in Japan (abstract C27]. First AnnualInternational Meeting for the Association for Pharmacoeconomicsand Outcomes Research: 1996 May 12: PhiladelphiaGoogle Scholar
  11. 11.
    Moriga M. Ikeda S. Reich MR. An analysis of pharmacoeconomic studies in Japan [in Japanesel. Iryo Keizai Kenkyu 1995;2: 73–83Google Scholar
  12. 12.
    Clemens K. Townsend R. Luscombe F. et al. Methodological and conduct principles for pharmacoeconomic research.Pharmacoeconomics 1995: 8: 169–74PubMedCrossRefGoogle Scholar
  13. 13.
    Drummond MF. Guidelines for pharmacoeconomic studies: the ways forward. Pharmacoeconomics 1994: 6: 493–7PubMedCrossRefGoogle Scholar
  14. 14.
    Drummond MF. Stoddart GL. Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press. 1987Google Scholar
  15. 15.
    Gold MR Siegel JE Russell LB et al editors. Cost-effectiveness in health and medicine. New York: Oxford University Press. 1996Google Scholar
  16. 16.
    Society of Japanese Pharmacopoeia. editor. Guidelines for the clinical evaluation for new drugs 1995 [in Japanese]. Tokyo: Yakuji Nippo. 1995Google Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Shunya Ikeda
    • 1
  • Naoki Ikegami
    • 1
  • Adam J. Oliver
    • 1
  • Mie Ikeda
    • 2
  1. 1.Department of Health Policy and Management, School of MedicineKeio UniversityJapan
  2. 2.Pharmaceutical Affairs BureauMinistry of Health and WelfareJapan

Personalised recommendations